human immortalized myoblasts  (PromoCell)

Journal: Rheumatology (Oxford, England)

Article Title: A novel estrogen receptor 1: sphingomyelin phosphodiesterase acid-like 3B pathway mediates rituximab response in myositis patients

doi: 10.1093/rheumatology/keac687

Figure Lengend Snippet: The impact of in vitro rituximab treatment on immortalized muscle cells. CCK-8, cell counting kit 8; ESR1, estrogen receptor 1; IL-13, interleukin 13; PBS, phosphate-buffered saline; TNF-α, tumor necrosis factor alpha. Raji (B-cells), THP-1 (macrophages) and immortalized human myoblasts and myotubes were treated with PBS or 5, 10 or 20 µg/mL rituximab. (A, B) Cell viability assessed by staining with trypan blue or with CCK-8 reagent. (C, D) Cytokine expression assessed using V-PLEX proinflammatory panel 1 (human) kit. (E) ESR1 expression measured using RTqPCR, fold change calculated by the 2-ΔΔCt method with HPRT1 as reference

Article Snippet: Immortalized muscle cells Immortalized human myoblasts (a kind gift from Dr Vincent Mouly at the Centre for Research in Myology in Paris, France) were grown at 3000 cells/cm 2 with skeletal muscle cell growth media (Promocell, Heidelberg, Germany) with 20% v/v fetal calf serum and 1% penicillin/streptomycin on flasks coated with 0.4% gelatin.

Techniques: In Vitro, CCK-8 Assay, Cell Counting, Saline, Staining, Expressing